In conclusion, the combination of lorlatinib and bevacizumab demonstrated activity and was safe in patients with heavily pretreated, ALK-rearranged lung cancers that had progressed on single-agent lorlatinib immediately before the combination. These findings add to a growing body of literature on the potential utility of antiangiogenic therapy with TKI therapy in oncogene-driven cancers. READ ARTICLE
JCO Precision Oncology DOI: 10.1200/PO.20.00271
Authors: Choudhury NJ, Young RJ, Sellitti M, Miller A, Drilon A.